azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone | 2133852-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone
• 英文别名: Zastaprazan；azetidin-1-yl-[8-[(2,6-dimethylphenyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]methanone
• CAS: 2133852-18-1
• 化学式: C₂₂H₂₆N₄O
• 分子量: 362.475
• InChiKey: FEQFUBYYZYQTOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  柠檬酸 、 azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone 以 丙酮 为溶剂， 生成 azetidin-1-yl-{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone citrate
  参考文献：
  名称：

  INJECTABLE COMPOSITION, PHARMACEUTICAL FORMULATION INCLUDING THE SAME, AND METHOD FOR PREPARING THE COMPOSITION

  摘要：

  The present invention relates to an injectable composition, a pharmaceutical formulation comprising the same, and a method for preparing the same The injectable composition according to the present invention comprises: azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]- 2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone citrate as active ingredient; and SBE-β- CD.

  公开号：

  WO2024161316A1

文献信息

• Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof
  申请人：Jeil Pharmaceutical Co., Ltd.

  公开号：US10696671B2

  公开（公告）日：2020-06-30

  The present disclosure relates to novel imidazo[1,2-a]pyridine derivatives, and more particularly to imidazo[1,2-a]pyridine derivatives of Formula 1 wherein Y1, Y2 and Y3 are each independently H, halogen, a C1-C6 straight chain alkyl unsubstituted or substituted with R1, or hydroxy; R1 is hydroxy; Y4 is H, C1-C6 straight chain alkyl, or C1-C6 alkoxy; and X is H or halogen, and having an excellent activity of inhibiting gastric acid secretion, methods for preparing the same, and the use thereof. The imidazo[1,2-a]pyridine derivatives according to the present disclosure have gastric acid secretion inhibitory activity, and thus may be effectively used for the prevention or treatment of gastrointestinal inflammatory diseases or gastric acid-related diseases.

  本公开涉及新型咪唑并[1,2-a]吡啶衍生物，特别是式 1 的咪唑并[1,2-a]吡啶衍生物 其中 Y1、Y2 和 Y3 各自独立地为 H、卤素、未被 R1 取代或取代的 C1-C6 直链烷基或羟基；R1 为羟基；Y4 为 H、C1-C6 直链烷基或 C1-C6 烷氧基；以及 X 为 H 或卤素、 及其制备方法和用途。根据本公开的咪唑并[1,2-a]吡啶衍生物具有胃酸分泌抑制活性，因此可有效用于预防或治疗胃肠道炎症疾病或胃酸相关疾病。
• IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USE THEREOF
  申请人：Jeil Pharmaceutical Co., Ltd.

  公开号：EP3481827B1

  公开（公告）日：2021-11-03
• Imidazo[1,2-A]Pyridine Derivatives, Methods for Preparing the Same and Use Thereof
  申请人：Jeil Pharmaceutical Co., Ltd.

  公开号：US20190152971A1

  公开（公告）日：2019-05-23

  The present disclosure relates to novel imidazo [1,2-α]pyridine derivatives, and more particularly to imidazo [1,2-α]pyridine derivatives having an excellent activity of inhibiting gastric acid secretion, methods for preparing the same, and the use thereof. The imidazo[1,2-α]pyridine derivatives according to the present disclosure have gastric acid secretion inhibitory activity, and thus may be effectively used for the prevention or treatment of gastrointestinal inflammatory diseases or gastric acid-related diseases.